MD4341C1 - Сироп для лечения предраковых состояний желудка - Google Patents
Сироп для лечения предраковых состояний желудка Download PDFInfo
- Publication number
- MD4341C1 MD4341C1 MDA20130088A MD20130088A MD4341C1 MD 4341 C1 MD4341 C1 MD 4341C1 MD A20130088 A MDA20130088 A MD A20130088A MD 20130088 A MD20130088 A MD 20130088A MD 4341 C1 MD4341 C1 MD 4341C1
- Authority
- MD
- Moldova
- Prior art keywords
- vitamin
- syrup
- treatment
- nanoparticles
- precancerous conditions
- Prior art date
Links
- 235000020357 syrup Nutrition 0.000 title claims abstract description 16
- 239000006188 syrup Substances 0.000 title claims abstract description 16
- 238000011282 treatment Methods 0.000 title claims abstract description 16
- 208000006994 Precancerous Conditions Diseases 0.000 title claims abstract description 11
- 230000002496 gastric effect Effects 0.000 title claims abstract description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 14
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 14
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 12
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000002105 nanoparticle Substances 0.000 claims abstract description 12
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 10
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 8
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 8
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 7
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 7
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229960002061 ergocalciferol Drugs 0.000 claims abstract description 7
- 229960002477 riboflavin Drugs 0.000 claims abstract description 7
- 229960003495 thiamine Drugs 0.000 claims abstract description 7
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims abstract description 7
- 235000001892 vitamin D2 Nutrition 0.000 claims abstract description 7
- 239000011653 vitamin D2 Substances 0.000 claims abstract description 7
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 6
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 6
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 6
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 6
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 6
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 6
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229910052709 silver Inorganic materials 0.000 claims abstract description 6
- 239000004332 silver Substances 0.000 claims abstract description 6
- 235000020374 simple syrup Nutrition 0.000 claims abstract description 6
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 6
- 239000011719 vitamin A Substances 0.000 claims abstract description 6
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 6
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 6
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 6
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 6
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 6
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 6
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 6
- 239000011718 vitamin C Substances 0.000 claims abstract description 6
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 6
- 239000011709 vitamin E Substances 0.000 claims abstract description 6
- 229940046009 vitamin E Drugs 0.000 claims abstract description 6
- 229940045997 vitamin a Drugs 0.000 claims abstract description 6
- 239000011787 zinc oxide Substances 0.000 claims abstract description 6
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000005751 Copper oxide Substances 0.000 claims abstract description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 5
- 229960002685 biotin Drugs 0.000 claims abstract description 5
- 235000020958 biotin Nutrition 0.000 claims abstract description 5
- 239000011616 biotin Substances 0.000 claims abstract description 5
- 229910000431 copper oxide Inorganic materials 0.000 claims abstract description 5
- 229960000304 folic acid Drugs 0.000 claims abstract description 5
- 235000019152 folic acid Nutrition 0.000 claims abstract description 5
- 239000011724 folic acid Substances 0.000 claims abstract description 5
- 239000000395 magnesium oxide Substances 0.000 claims abstract description 5
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims abstract description 5
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 5
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 5
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 5
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 5
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 5
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000011655 sodium selenate Substances 0.000 claims abstract description 4
- 229960001881 sodium selenate Drugs 0.000 claims abstract description 4
- 235000018716 sodium selenate Nutrition 0.000 claims abstract description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract 3
- 239000004615 ingredient Substances 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 4
- 239000013543 active substance Substances 0.000 abstract description 3
- 235000012245 magnesium oxide Nutrition 0.000 abstract description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 abstract 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 abstract 1
- 229960004643 cupric oxide Drugs 0.000 abstract 1
- 229960000869 magnesium oxide Drugs 0.000 abstract 1
- 229940055726 pantothenic acid Drugs 0.000 abstract 1
- 235000019161 pantothenic acid Nutrition 0.000 abstract 1
- 239000011713 pantothenic acid Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 5
- 230000002411 adverse Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 235000014066 European mistletoe Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 235000012300 Rhipsalis cassutha Nutrition 0.000 description 2
- 240000007313 Tilia cordata Species 0.000 description 2
- 241000221012 Viscum Species 0.000 description 2
- 239000011852 carbon nanoparticle Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- -1 polyethylene terephthalate Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XWKBMOUUGHARTI-UHFFFAOYSA-N tricalcium;diphosphite Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])[O-].[O-]P([O-])[O-] XWKBMOUUGHARTI-UHFFFAOYSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004231 Riboflavin-5-Sodium Phosphate Substances 0.000 description 1
- 241000983746 Saccharina latissima Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 235000000336 Solanum dulcamara Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- TVZISJTYELEYPI-UHFFFAOYSA-N hypodiphosphoric acid Chemical compound OP(O)(=O)P(O)(O)=O TVZISJTYELEYPI-UHFFFAOYSA-N 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- 229960003035 magnesium gluconate Drugs 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000011683 manganese gluconate Substances 0.000 description 1
- 235000014012 manganese gluconate Nutrition 0.000 description 1
- 229940072543 manganese gluconate Drugs 0.000 description 1
- OXHQNTSSPHKCPB-IYEMJOQQSA-L manganese(2+);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Mn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OXHQNTSSPHKCPB-IYEMJOQQSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000019234 riboflavin-5-sodium phosphate Nutrition 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 208000005057 thyrotoxicosis Diseases 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относится к гастроэнтерологии, в частности к биологически активным веществам в виде сиропов, которые могут быть использованы для лечения предраковых состояний желудка.Согласно изобретению, заявленный сироп состоит из: витамин А, витамин D2, витамин Е, витамин С, витамин B1, витамин B2, ниацин, витамин B6, витамин B12, биотин, фолиевая кислота, пантотеновая кислота, оксид магния, оксид меди, селенат натрия, наночастицы оксида цинка и серебра, взятые в соотношении 9:1, и сахарный сироп, при следующем количественном соотношении компонентов, на 100 мл:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDA20130088A MD4341C1 (ru) | 2013-11-21 | 2013-11-21 | Сироп для лечения предраковых состояний желудка |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDA20130088A MD4341C1 (ru) | 2013-11-21 | 2013-11-21 | Сироп для лечения предраковых состояний желудка |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD4341B1 MD4341B1 (ru) | 2015-04-30 |
| MD4341C1 true MD4341C1 (ru) | 2015-11-30 |
Family
ID=53002924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDA20130088A MD4341C1 (ru) | 2013-11-21 | 2013-11-21 | Сироп для лечения предраковых состояний желудка |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD4341C1 (ru) |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991002535A1 (en) * | 1989-08-11 | 1991-03-07 | Basil, Inc. | Cancer prevention composition and method |
| DE4032163C2 (de) * | 1990-10-10 | 1995-03-30 | Gradinger F Hermes Pharma | S-Retinoyl-L-aminomercapto-Verbindungen und Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung |
| DE4032187C2 (de) * | 1990-10-10 | 1995-03-30 | Gradinger F Hermes Pharma | N-Retinoyl-L-aminomercapto-Verbindungen und Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung |
| RU2034560C1 (ru) * | 1993-05-18 | 1995-05-10 | Товарищество с ограниченной ответственностью "Фитолон" | Средство для профилактики рака "кламин" |
| CN1093402C (zh) * | 1998-08-11 | 2002-10-30 | 苏乐群 | 一种治疗胃炎的片剂 |
| RU2205656C1 (ru) * | 2002-06-27 | 2003-06-10 | Общество с ограниченной ответственностью Фирма "ЭЙКОСЪ" | Биологически активная добавка "антиязвенные" для профилактики и поддерживающей терапии заболеваний желудочно-кишечного тракта |
| NZ529115A (en) * | 2001-04-20 | 2005-08-26 | Boehringer Ingelheim Pharma | Use of probucol, ascorbic acid, vitamin E, dipyridamole and mopidamol for treatment and prevention of NO-dependent microcirculation disorders |
| CN1698646A (zh) * | 2005-04-29 | 2005-11-23 | 朱舜时 | 治疗萎缩性胃炎的药物组合物 |
| CN1927311A (zh) * | 2006-09-19 | 2007-03-14 | 陈楚挺 | 治疗慢性萎缩性胃炎癌前病变的药物与其成品胶囊 |
| MD3972C2 (ru) * | 2009-03-11 | 2010-07-31 | Ион МЕРЕУЦЭ | Средство и метод лечения предраковых состояний |
| RU2473357C2 (ru) * | 2011-02-24 | 2013-01-27 | Общество с ограниченной ответственностью "ДИНАМИК ДЕВЕЛОПМЕНТ ЛАБОРАТОРИЗ" | Жидкая композиция, повышающая работоспособность и обладающая адаптогенным, ранозаживляющим, противовоспалительным действием |
| CN103230431A (zh) * | 2013-04-27 | 2013-08-07 | 洪士炀 | 治疗胃病的药物及用途 |
| CN103082299B (zh) * | 2012-12-26 | 2014-07-30 | 东莞市照燕生物科技有限公司 | 一种清肠排毒的营养保健品 |
-
2013
- 2013-11-21 MD MDA20130088A patent/MD4341C1/ru not_active IP Right Cessation
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991002535A1 (en) * | 1989-08-11 | 1991-03-07 | Basil, Inc. | Cancer prevention composition and method |
| DE4032163C2 (de) * | 1990-10-10 | 1995-03-30 | Gradinger F Hermes Pharma | S-Retinoyl-L-aminomercapto-Verbindungen und Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung |
| DE4032187C2 (de) * | 1990-10-10 | 1995-03-30 | Gradinger F Hermes Pharma | N-Retinoyl-L-aminomercapto-Verbindungen und Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung |
| RU2034560C1 (ru) * | 1993-05-18 | 1995-05-10 | Товарищество с ограниченной ответственностью "Фитолон" | Средство для профилактики рака "кламин" |
| CN1093402C (zh) * | 1998-08-11 | 2002-10-30 | 苏乐群 | 一种治疗胃炎的片剂 |
| NZ529115A (en) * | 2001-04-20 | 2005-08-26 | Boehringer Ingelheim Pharma | Use of probucol, ascorbic acid, vitamin E, dipyridamole and mopidamol for treatment and prevention of NO-dependent microcirculation disorders |
| RU2205656C1 (ru) * | 2002-06-27 | 2003-06-10 | Общество с ограниченной ответственностью Фирма "ЭЙКОСЪ" | Биологически активная добавка "антиязвенные" для профилактики и поддерживающей терапии заболеваний желудочно-кишечного тракта |
| CN1698646A (zh) * | 2005-04-29 | 2005-11-23 | 朱舜时 | 治疗萎缩性胃炎的药物组合物 |
| CN1927311A (zh) * | 2006-09-19 | 2007-03-14 | 陈楚挺 | 治疗慢性萎缩性胃炎癌前病变的药物与其成品胶囊 |
| MD3972C2 (ru) * | 2009-03-11 | 2010-07-31 | Ион МЕРЕУЦЭ | Средство и метод лечения предраковых состояний |
| RU2473357C2 (ru) * | 2011-02-24 | 2013-01-27 | Общество с ограниченной ответственностью "ДИНАМИК ДЕВЕЛОПМЕНТ ЛАБОРАТОРИЗ" | Жидкая композиция, повышающая работоспособность и обладающая адаптогенным, ранозаживляющим, противовоспалительным действием |
| CN103082299B (zh) * | 2012-12-26 | 2014-07-30 | 东莞市照燕生物科技有限公司 | 一种清肠排毒的营养保健品 |
| CN103230431A (zh) * | 2013-04-27 | 2013-08-07 | 洪士炀 | 治疗胃病的药物及用途 |
Non-Patent Citations (1)
| Title |
|---|
| Регистр лекарственных средств. Энциклопедия лекарств. Выпуск 21, 2012, p. 1426 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MD4341B1 (ru) | 2015-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stansbury et al. | Promoting healthy thyroid function with iodine, bladderwrack, guggul and iris | |
| CN103223128B (zh) | 一种改善营养性贫血的中药组合物及其制备方法 | |
| CN110800997A (zh) | 一种甲状腺癌专用型临床营养配方及其制备方法 | |
| US9943503B1 (en) | Pharmaceutical composition for treating bacterial and viral infections | |
| CN106165905A (zh) | 一种钙加维生素软胶囊及制备方法 | |
| WO2015190875A1 (ko) | 스피루리나 추출물을 유효성분으로 함유하는 망막질환 예방 및 치료용 약학적 조성물 | |
| CN102268098B (zh) | 墨旱莲多糖铁络合物制备方法及其应用 | |
| MD4341C1 (ru) | Сироп для лечения предраковых состояний желудка | |
| CN105395644A (zh) | 一种用于防治鸡球虫病的中药组合物及其制备方法和应用 | |
| US10149831B1 (en) | Pharmaceutical composition for treating bacterial and viral infections | |
| US20190247360A1 (en) | Pharmaceutical Composition for Treating Bacterial and Viral infections | |
| JP4610730B2 (ja) | カルシウム補給用の組成物 | |
| CN114468291A (zh) | 一种改善女性不孕的肌醇组合物及其制备方法 | |
| RU2821515C1 (ru) | Композиция на основе растительного сырья для профилактики воспалительных заболеваний почек и мочевых путей | |
| CN104027351A (zh) | 一种口服补充剂的组合物 | |
| BR112016005727B1 (pt) | Uso de um extrato de polifenol de cacau para preparação de uma composição para tratamento de esofagite eosinofílica | |
| US11931393B2 (en) | Biologically active food additive for normalizing the function of the thyroid gland | |
| CN101396411B (zh) | 用于优生优育预防出生缺陷并且改善记忆的药物组合物 | |
| RU2442599C2 (ru) | ГОМЕОПАТИЧЕСКОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО И БИОЛОГИЧЕСКИ АКТИВНАЯ ДОБАВКА К ПИЩЕ, СОДЕРЖАЩИЕ Nisylen, Сера, Euphrasia, Belladonna И/ИЛИ Mercurius solubilis | |
| US10166265B1 (en) | Pharmaceutical composition for treating bacterial and viral infections | |
| Obu | Aloe vera: a natural constipation relief remedy, treats diabetes, improves skin, and dental Health. | |
| Peres | Iodine, Ingesting or not | |
| CN104274625B (zh) | 一种中药在治疗少精子疾病中的应用 | |
| CN104069256A (zh) | 用于预防出生缺陷和改善记忆的药物组合物 | |
| CN102935132B (zh) | 一种排铅中药组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG4A | Patent for invention issued | ||
| KA4A | Patent for invention lapsed due to non-payment of fees (with right of restoration) | ||
| MM4A | Patent for invention definitely lapsed due to non-payment of fees |